Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5838-5847

  Spector, Neil L ^a   Blackwell, Kimberly L ^a  

^a DUKE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERTUZUMAB; TANESPIMYCIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; BREAST TUMOR; FEMALE; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PATIENT SELECTION; RECEPTOR, ERBB-2;

EID: 73349085919     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.1507     Document Type: Review

References (114)

1. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
2. Park JW, Neve RM, Szollosi J, et al: Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8:392-401, 2008
3. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467, 1996
4. Graus-Porta D, Beerli RR, Daly JM, et al: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655, 1997
5. Hellyer NJ, Cheng K, Koland JG: ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 333:757-763, 1998
6. Camirand A, Lu Y, Pollak M: Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8:BR521-PR526, 2002
7. Lu Y, Zi X, Zhao Y, et al: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857, 2001
8. Harris LN, You F, Schnitt SJ, et al: Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207, 2007
9. Sjögren S, Inganas M, Lindgren A, et al: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
10. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
11. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004
12. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
13. Ferlay J, Autier P, Boniol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592, 2007
14. Makino K, Day CP, Wang SC, et al: Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. Oncogene 23:3883-3887, 2004
15. Bacus SS, Altomare DA, Lyass L, et al: AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21:3532-3540, 2002
16. Xia W, Bisi J, Strum J, et al: Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66:1640-1647, 2006
17. Yakes FM, Chinratanalab W, Ritter CA, et al: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132-4141, 2002
18. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
19. Fendly BM, Kotts C, Vetterlein D, et al: The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod 9:449-455, 1990
20. Lewis GD, Figari I, Fendly B, et al: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993
21. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
22. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
23. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004
24. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
25. Pietras RJ, Pegram MD, Finn RS, et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-2249, 1998
26. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
27. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
28. Pegram M, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
29. Pegram MD, Lopez A, Konecny G, et al: Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27:21-25, 2000 (suppl 11); discussion 92-100
30. Merlin JL, Barberi-Heyob M, Bachmann N: In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol 13:1743-1748, 2002
31. Argiris A, Wang C-X, Whalen SG, et al: Synergistic interaction between tamoxifen and trastuzumab. Clin Cancer Res 10:1409-1420, 2004
32. Lazar GA, Dang W, Karki S, et al: Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103:4005-4010, 2006
33. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446, 2000
34. Cooley S, Burns LJ, Repka T, et al: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibodydependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27:1533-1541, 1999
35. Mimura M, Kono K, Hanawa M, et al: Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11:4898-4904, 2005
36. Repka T, Chiorean EG, Gay J, et al: Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: A pilot study. Clin Cancer Res 9:2440-2446, 2003
37. Arnould L, Gelly M, Penault-Llorca F, et al: Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267, 2006
38. Banna GL, Aversa SM, Crivellari G: Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer. Br J Cancer 94:1550-1552, 2006
39. Gennari R, Menard S, Fagnoni F, et al: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655, 2004
40. Musolino A, Naldi N, Bortesi B, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796, 2008
41. Gianni L: The "other" signaling of trastuzumab: Antibodies are immunocompetent drugs. J Clin Oncol 26:1778-1780, 2008
42. Carney WP, Neumann R, Lipton A, et al: Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 5:105-116, 2004
43. Fornier MN, Seidman AD, Schwartz MK, et al: Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16:234-239, 2005
44. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393-9398, 2004
45. Köstler WJ, Steger GG, Soleiman A, et al: Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 24:1127-1130, 2004
46. Scaltriti M, Rojo F, Ocana A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638, 2007
47. Molina MA, Codony-Servat J, Albanell J, et al: Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744-4749, 2001
48. Xia W, Liu L-H, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646-653, 2004
49. Anido J, Scaltriti M, Bech Serra JJ, et al: Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25:3234-3244, 2006
50. Neve RM, Holbro T, Hynes NE: Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 21:4567-4576, 2002
51. Xia W, Chen JS, Zhou X, et al: Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10:3815-3824, 2004
52. Xia W, Mullin RJ, Keith BR, et al: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263, 2002
53. Asanuma H, Torigoe T, Kamiguchi K, et al: Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65:11018-11025, 2005
54. Le XF, Lammayot A, Gold D, et al: Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280:2092-2104, 2005
55. Zhou W, Carpenter G: Heregulin-dependent translocation and hyperphosphorylation of ErbB-2. Oncogene 20:3918-3920, 2001
56. Sabbatini P, McCormick F: Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated transcriptionally dependent apoptosis. J Biol Chem 274:24263-24269, 1999
57. Le XF, Claret FX, Lammayot A, et al: The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278:23441-23450, 2003
58. Le XF, Pruefer F, Bast RC Jr: HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4:87-95, 2005
59. Lane HA, Motoyama AB, Beuvink I, et al: Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 1:S21-S22, 2001 (suppl 12)
60. Izumi Y, Xu L, di Tomasco E, et al: Tumor biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416:279-280, 2002
61. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355, 1999
62. Soderlund K, Perez-Tenorio G, Stal O: Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. Int J Oncol 26:25-32, 2005
63. Yu D, Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19:6115-6121, 2000
64. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
65. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
66. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
67. Perez EA, Romond EH, Suman V, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25:6s, 2007 (suppl 18; abstr 512)
68. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
69. Smith I, Proter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007
70. Slamon DJ, Eiermann W, Robert N, et al: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: Second interim efficacy analysis. Breast Cancer Res Treat 100, 2006 (suppl 63; abstr 52)
71. Joensuu H, Bono P, Kataja V, et al: Update of the FINHER trial based on 5 years of followup. Breast 18:S10, 2009 (suppl 1; abstr S24)
72. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
73. Hicks DG, Kulkarni S: HER2+ breast cancer: Review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 129:263-273, 2008
74. Paik S: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409-1411, 2008
75. Kaufman PA, Broadwater G, Lezon-Geyda K: CALGB 150002: correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2 and HER2- metastatic breast cancer (MBC). J Clin Oncol 25:34s, 2007 (suppl 18; abstr 1009)
76. Kim C, Bryant J, Horne Z, et al: Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 94:S6, 2005 (suppl 1, abstr 46)
77. Perez EA, Reinholz MM, Dueck AC, et al: C-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831. Cancer Res 69:76s, 2009 (suppl; abstr 56)
78. Menendez JA, Mehmi I, Lupu R: Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24:3735-3746, 2006
79. Spears M, Munro AF, Taylor KJ, et al: The use of proximity ligation assay to identify HER2: HER3 heterodimers in early breast cancers. Cancer Res 69:176s, 2009 (suppl; abstr 2068)
80. Mukherjee A, Badal Y, Nguyen X-T, et al: Proximity-based assays for the detection of activated HER3, HER2/HER3 heterodimers and HER3/PI3K complexes in formalin-fixed, paraffin-embedded cell line controls and tumors. Cancer Res 69:269s, 2009 (suppl; abstr 4040)
81. Nahta R, Esteva FJ: HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215, 2006
82. Nahta R, Yu D, Hung MC, et al: Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Prac Oncol 3:269-280, 2006
83. Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62:3151-3158, 2002
84. Nahta R, Yuan LX, Zhang B, et al: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128, 2005
85. Nahta R, Takahashi T, Ueno NT, et al: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64:3981-3986, 2004
86. Lu Y, Zi X, Pollak M: Molecular mechanisms underlying IGF-I-induced attenuation of the growthinhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108:334-341, 2004
87. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007
88. Fujita T, Doihara H, Kawasaki K, et al: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94:247-252, 2006
89. Fujita T, Doihara H, Washio K, et al: Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 17:455-462, 2006
90. Lu CH, Wyszomierski SL, Tseng LM, et al: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13:5883-5888, 2007
91. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
92. Nagy P, Friedlander E, Tanner M, et al: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473-482, 2005
93. Prempree C, Wongpaksa T: Mutations of HER2 gene in HER2-positive metastatic breast cancer. J Clin Oncol 24:611s, 2006 (suppl 18; abstr 13118)
94. von Minckwitz G, Zielinski C, Maarteense E, et al: Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 26:47s, 2008 (suppl 15; abstr 1025)
95. O'Shaughnessy JA, Blackwell KL, Burstein H, et al: A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2-positive metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26:44s, 2008 (suppl 15; abstr 1015)
96. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
97. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
98. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
99. Portera CC, Walshe JM, Denduluri N, et al: A report of cardiac events in a phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer (MBC). J Clin Oncol 25:39s, 2007 (suppl 18; abstr 1028)
100. Baselga J, Cameron D, Miles D, et al: Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol 25:33s, 2007 (suppl 18; abstr 1004)
101. Xia W, Gerard CM, Liu L, et al: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24:6213-6221, 2005
102. Storniolo AM, Pegram MD, Overmoyer B, et al: Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 26:3317-3323, 2008
103. Dang CT, Lin NU, Lake D, et al: Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). J Clin Oncol 26:11s, 2008 (suppl 15)
104. Burstein HJ, Sun Y, Tan AR, et al: Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: Phase 2 results in patients with advanced HER2+ breast cancer. Cancer Res 69:76s, 2009 (suppl; abstr 37)
105. Pegram M, Chan D, Dichmann RA, et al: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100:S28, 2006 (suppl 1; abstr 301)
106. Xu W, Mimnaugh E, Rosser MFN, et al: Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276:3702-3708, 2001
107. Modi S, Stopeck A, Linden HM, et al: Phase II trial of trastuzumab and KOS-953 (tanespimycin) in patients with HER2-positive breast cancer: Preliminary results. Breast Cancer Res Treat 100:S72, 2006 (suppl 1; abstr 1102)
108. Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8:191-195, 2001
109. Witters L, Engle L, Lipton A: Restoration of estrogen responsiveness by blocking the HER-2/neupathway. Oncol Rep 9:1163-1166, 2002
110. Kaufman B, Mackey J, Clemens M, et al: Trastuzumab plus anastrozole in postmenopausal women with HER2-positive, HR-positive MBC: Results of the TAnDEM study. Ann Oncol 17, 2006 (suppl 9; abstr LBA2), http://annonc.oxfordjournals. org/cgi/reprint/suppl-9/NP
111. Mackey JR, Kaufman B, Clemens M, et al: Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 100:S5, 2006 (suppl 1; abstr 3)
112. Johnston S, Pegram M, Press M, et al: Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): First results from the EGF30008 Trial. Cancer Res 69:74s, 2009 (suppl; abstr 46)
113. Beeram M, Burris HA III, Modi S, et al: A phase I study of trastuzumab-DM1 (T-DM1), a firstin-class HER2 antibody-drug conjugate (ADC) in patients with advanced HER2+ breast cancer. J Clin Oncol 26:48s, 2008 (suppl 15; abstr 1028)
114. Vukelja S, Rugo H, Vogel C, et al: A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. Cancer Res 69:71s, 2009 (suppl; abstr 33)